WICHITA, Kan., Jan. 22, 2017 -- Patients can effectively relieve dry eyes with the advanced technology provided from LipiFlow® gland function treatment. Wichita Optometry is one of the first in the area to offer LipiFlow®, a revolutionary treatment for dry eye disease associated with Meibomian Gland Dysfunction (MGD). MGD is the leading cause of most forms of dry eye disease. Dry eye disease is progressive and may affect individuals of any age. Dry eyes can impair vision and interfere with the ability to read, drive, and perform routine activities.
Dry eye disease is a progressive condition that was once thought to affect only older adults. MGD-related dry eye disease affects people of all ages and is influenced by many factors including use of digital devices and computer-intensive work environments. Research shows that fluctuating vision (blurrier vision at certain times of the day) is one of the most common patient complaints. Other symptoms include irritated, gritty, scratchy, or burning eyes, a feeling of something in the eyes, excess watering, and blurred vision. Without treatment, dry eye disease progresses over time and can affect vision and quality of life.
LipiFlow® is fast, painless and can substantially improve the quality of life for dry eye sufferers. Shown to provide comfort to 86% of dry eye patients, LipiFlow® is the only FDA Cleared technology to address one of the main root causes. Treatments with LipiFlow® undertaken by the end of the year can be covered using remaining FSA/HSA dollars with Dr. Chad Fleming of Wichita Optometry.
“Dry eye is one of the most common complaints I hear from patients, and it’s one that shouldn’t be ignored,” said Chad Fleming, OD, FAAO. “We are pleased to now offer LipiFlow® to help those with MGD. We know that traditional therapies provide limited relief. LipiFlow® can bring comfort back to a dry eye sufferer’s life. Dry eye sufferers can now get effective Meibomian Gland Dysfunction (MGD) treatment in Wichita. I can’t stress enough how important it is to care for your eye health and not let dry eye go untreated.”
Dr. Chad Fleming is one of the optometrists available at Wichita Optometry, serving the vision needs of residents in and around Wichita, KS at one of their two locations on West Douglas Avenue or on North Amidon. Patients can expect friendly and high-quality eye care from staff who address any patient concerns. Services at Wichita Optometry include comprehensive eye exams, eyeglasses, contact lenses, pre- and post-operative care, and treatment of eye diseases including pink eye, diabetic retinopathy, astigmatism, cataracts, glaucoma, macular degeneration, dry eyes, red eyes and amblyopia.
Call (316) 942-7496 for their West Douglas Avenue location and (316) 838-7797 for their North Amidon location to learn more about LipiFlow® gland function treatment. For all suffering from dry eyes in the Wichita area, visit http://www.eyedoctorwichita.com/.
Wichita Optometry, (316) 942-7496


Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Italy Fines Apple €98.6 Million Over App Store Dominance
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



